7RBS image
Deposition Date 2021-07-06
Release Date 2021-09-29
Last Version Date 2024-11-13
Entry Detail
PDB ID:
7RBS
Keywords:
Title:
The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15
Biological Source:
Method Details:
Experimental Method:
Resolution:
2.98 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Papain-like protease
Mutations:C111S
Chain IDs:A, C, E, G, I
Chain Length:318
Number of Molecules:5
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Molecule:Ubiquitin-like protein ISG15
Gene (Uniprot):ISG15
Chain IDs:B, D, F, H, J
Chain Length:159
Number of Molecules:5
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin.
Nat Commun 14 2366 2366 (2023)
PMID: 37185902 DOI: 10.1038/s41467-023-38031-5

Abstact

The Papain-like protease (PLpro) is a domain of a multi-functional, non-structural protein 3 of coronaviruses. PLpro cleaves viral polyproteins and posttranslational conjugates with poly-ubiquitin and protective ISG15, composed of two ubiquitin-like (UBL) domains. Across coronaviruses, PLpro showed divergent selectivity for recognition and cleavage of posttranslational conjugates despite sequence conservation. We show that SARS-CoV-2 PLpro binds human ISG15 and K48-linked di-ubiquitin (K48-Ub2) with nanomolar affinity and detect alternate weaker-binding modes. Crystal structures of untethered PLpro complexes with ISG15 and K48-Ub2 combined with solution NMR and cross-linking mass spectrometry revealed how the two domains of ISG15 or K48-Ub2 are differently utilized in interactions with PLpro. Analysis of protein interface energetics predicted differential binding stabilities of the two UBL/Ub domains that were validated experimentally. We emphasize how substrate recognition can be tuned to cleave specifically ISG15 or K48-Ub2 modifications while retaining capacity to cleave mono-Ub conjugates. These results highlight alternative druggable surfaces that would inhibit PLpro function.

Legend

Protein

Chemical

Disease

Primary Citation of related structures